Boston Scientific Corporation vs Endeavour Silver Corp — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Endeavour Silver Corp trades at $10.73 (market cap $3.03B). The key difference: Boston Scientific Corporation is far larger — about 23.6× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | EXK | |
|---|---|---|
Market Cap | $71.46B | $3.03B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $14.12 |
52-Week Low | $42.63 | $5.31 |
Enterprise Value | $83.55B | $3.04B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
EXK is trading at $9.54, up 8.04% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with Q2 2026 earnings matching estimates and revenue growth from $468M in 2025 to $737M projected for 2026. Recent news highlights a $25M credit facility and operational expansion at Terronera mine.
Outlook remains positive with analyst consensus price target of $15.50 (62% upside), though risks include volatile earnings history and elevated P/E ratio of 51.2. The stock offers growth potential through silver production expansion but faces commodity price sensitivity and execution risks in mine development.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →